Drugs / CKD-701
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04857177 | Oct 2018 → Mar 2021 | wet macular degeneration | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04857177 ↗ |
| Known as | ranibizumab | “CKD-701 (proposed ranibizumab biosimilar)” NCT04857177 ↗ |
| Route | Intravitreal | “via intravitreal injection” NCT04857177 ↗ |